Use of an anti‐CD200‐blocking antibody improves immune responses to AML in vitro and in vivo
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.17125
Abstract: Treatment of relapsed/resistant acute myeloid leukaemia (AML) remains a significant area of unmet patient need, the outlook for most patients remaining extremely poor. A promising approach is to augment the anti‐tumour immune response in these… read more here.
Keywords: vitro vivo; anti cd200; antibody; immune responses ... See more keywords